• 1
    Pappas PG, Kaufmann C, Alexander B et al. Prospective surveillance of invasive fungal infections (IfIs) among organ transplant recipients (OTRs) in the U.S. 2001–2006. 47th Interscience Conference on Anticrobial Agents and Chemotherapy, Chicago, IL, September 17–20, 2007.
  • 2
    Husain C, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: Variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7: 375381.
  • 3
    Singh N, Alexander BD, Lortholary O et al. Cryptococcus neoformans in organ transplant recipients: Impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195: 756764.
  • 4
    Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999; 37: 32043209.
  • 5
    Haugen RK, Baker RD. The pulmonary lesions in cryptococcosis with special reference to subpleural nodules. Am J Clin Pathol 1954; 37: 13811390.
  • 6
    Saha DC, Goldman DL, Shao X et al. Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin Vaccine Immunol 2007; 14: 15501554.
  • 7
    Kapoor A, Flenchner SM, O’Malley K, Paolone D, File TM Jr, Cutrona AF. Cryptococcal meningitis in renal transplant patients associated with environmental exposure. Transplant Infect Dis 1999; 1: 213217.
  • 8
    Neuville S, Dromer F, Morin O, Dupont B, Ronin O, Lortholary O. Primary cutaneous cryptococcosis: A distinct clinical entity. Clin Infect Dis 2003; 36: 337347.
  • 9
    Nosanchuk JD, Shoham S, Fries BC, Shapiro DS, Levitz SM, Casadevall A. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann Intern Med 2000; 132: 205208.
  • 10
    Beyt BE Jr, Waltman SR. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med 1978; 15: 825826.
  • 11
    Kanj SS, Welty-Wolf K, Madden J et al. Fungal infections in lung and heart-lung transplant recipients: Report of 9 cases and review of the literature. Medicine 1996; 75: 142156.
  • 12
    Ooi HS, Chen BTM, Cheng HL, Khoo OT, Chan KT. Survival of a patient transplanted with a kidney infected with Cryptococcus neoformans. Transplantation 1971; 11: 428429.
  • 13
    Gorlach J, Fox DS, Cutler NS, Cox GM, Perfect JR, Heitman J. Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. EMBO J 2000; 19: 112.
  • 14
    Baddley JW, Perfect JR, Oster RA et al. Pulmonary cryptococccosis in patients without HIV infection: Factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 2008; 27: 937943.
  • 15
    Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis: A study in 111 cases. Ann Intern Med 1974; 80: 176181.
  • 16
    Dromer F, Mathoulin S, Dupont B, Laporte A, and the French Cryptococcosis G. Epidemiology of cryptococcosis in France: A 9-year survey (1985–1993). Clin Infect Dis 1996; 23: 8290.
  • 17
    Pappas PG, Perfect JR, Cloud GA et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33: 690699.
  • 18
    Vilchez RA, Fung J, Kusne S. Cryptococcosis in organ transplant recipients: An overview. Am J Transplant 2002; 2: 575580.
  • 19
    Silveira EP, Husain S, Kwak EJ et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transplant Infect Dis 2007; 9: 2227.
  • 20
    Peleg AY, Husain S, Kwak EJ et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal DC-52 antibody. Clin Infect Dis 2007; 44: 204212.
  • 21
    Jarvis JN, Harrison TS. Pulmonary cryptococcosis. Semin Respir Crit Care Med 2008; 29: 141150.
  • 22
    French Cryptococcal Study Group. unpublished data, 2008.
  • 23
    West SK, Bryrnes E, Mostad S. Emergence of Cryptococcus gattii in the Pacific Northwest United States. 48th Annual ICAAC/IDSA 46th Annual Meeting Washington, DC, October 25–28, 2008.
  • 24
    MacDougall L, Kidd SE, Galanis E et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 2007; 13: 4250.
  • 25
    Jabbour N, Reyes J, Kusne S, Martin M, Fung J. Cryptococcal meningitis after liver transplantation. Transplantation 1996; 61: 146167.
  • 26
    Wu G, Vilchez RA, Eidelman B, Fung J, Kormos R, Kusne S. Cryptococcal meningitis: An analysis among 5521 consecutive organ transplant recipients. Transplant Infect Dis 2002; 4: 183188.
  • 27
    Singh N, Lortholary O, Dromer F et al. Central nervous system cryptococcosis in solid organ transplant recipients: Clinical relevance of abnormal neuroimaging findings. Transplantation 2008; 56: 647651.
  • 28
    Mueller NJ, Fishman JA. Asymptomatic pulmonary cryptococcosis in solid organ transplantation: Report of four cases and review of the literature. Transplant Infect Dis 2003; 5: 140143.
  • 29
    Casadevall A. What is the latest approach to pulmonary cryptococcosis. J Respir Dis 2004; 25: 188199.
  • 30
    Gloster HM Jr, Swerlick RA, Solomon AR. Cryptococcal cellulitis in a diabetic kidney transplant patient. J Am Acad Dermatol 1994; 30: 10251026.
  • 31
    Horrevorts AM, Huysmans FTM, Koopman RJJ, Jacques F, Meis GM. Cellulitis as first clinical presentation of disseminated cryptococcosis in renal transplant recipients. Scand J Infect Dis 1994; 26: 623626.
  • 32
    Kontoyiannis DP, Lewis RE, Alexander BD et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates; Correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemotherap 2008; 52: 735738.
  • 33
    Pirofski LA, Casadevall A. The damage-response framework of microbial pathogenesis and infectious diseases. Adv Exp Med Biol 2008; 635: 135146.
  • 34
    Lanternier F, Chandesris MO, Poire S et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant 2007; 12: 28262828.
  • 35
    Singh N, Lortholary O, Alexander BD et al. An “immune reconstitution syndrome”-like entity associated with Cryptococcus neoformans infections in organ transplant recipients. Clin Infect Dis 2005; 40: 17561761.
  • 36
    D’Elios MM, Josien R, Manghetti M et al. Predominant Th1 cell infiltration in acute rejection episodes of human kidney grafts. Kidney Int 1997; 51: 18761884.
  • 37
    Gras J, Wieers G, Vaerman JL et al. Early immunological monitoring after pediatric liver transplantation: Cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl 2007; 13: 426433.
  • 38
    Dilhuydy MS, Jouary T, Demeaux H, Ravaud A. Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia. Br J Haematol 2007; 137: 490.
  • 39
    Ferraris JR, Tambutti ML, Cardoni RL, Prigoshin N. Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: Changes in the immune responses. Transplantation 2004; 77: 532537.
  • 40
    Hodge S, Hodge G, Flower R, Han P. Methyl-prednisolone upregulates monocyte IL-10 production in stimulated whole blood. Scand J Immunol 1999; 49: 548553.
  • 41
    Singh N. Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses. Eur J Clin Microbiol Infect Dis 2008 Epub ahead of print; 27: 403408.
  • 42
    Ingram PR, Howman R, Leahy MF, Dyer JR. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis 2007; 44: e115e7.
  • 43
    Singh N, Forrest G, Sifri C et al. Cryptococcus-associated immune reconstitution syndrome (IRS) in solid organ transplant (SOT) recipients: Results from a prospective, Multicenter Study (abstract #2152). 48th Annual ICAAC/IDSA 46th Annual Meeting Washington, DC, October 25–28, 2008, 2008.
  • 44
    Singh N, Lortholary O, Alexander BD et al. Allograft loss in renal transplant recipients with C. neoformans associated immune reconstitution syndrome. Transplantation 2005; 80: 11311133.
  • 45
    Charlier C, Dromer F, Leveque C et al. Cryptococcal neuroradiological lesions correlate with severity during Cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PloS One 2008; 3: E1950.
  • 46
    Dromer F, Mathoulin-Plissier S, Launay O, Lortholary O, French Cryptococcis Study G. Determinants of disease presentation and outcome during cryptococcosis: The CryptoA/D study. Plo S Med 2007; 4: e21.
  • 47
    Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710718.
  • 48
    Graybill JR, Sobel J, Saag M et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and Cryptococcal meningitis. Clin Infect Dis 2000; 30: 4754.
  • 49
    White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: Outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992; 165: 960962.
  • 50
    Ikeda R, Sugita T, Shinoda T. Serological relationships of Cryptococcus spp.: Distribution of antigenic factors in Cryptococcus and intraspecies diversity. J Clin Microbiol 2000; 38: 40214025.
  • 51
    Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Non-neoformans cryptococcal infections: A systematic review. Infection 2007; 35: 5158.
  • 52
    McCurdy LH, Morrow JD. Infections due to non-neoformans cryptococcal species. Compr Ther 2003 Summer-Fall; 29: 95101.
  • 53
    Paterson DL, Singh N, Gayowski T, Marino IR. Pulmonary nodules in liver transplant recipients. Medicine 1998; 77: 5058.
  • 54
    Singh N, Alexander BD, Lortholary O et al. Pulmonary cryptococcosis in solid organ transplant recipients: Clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008; 46: e12e18.
  • 55
    Thompson GRR, Wiederhold NP, Forhergill AW, Vallor AC, Wickes BL, Patterson TF. Antifungal suceptibilities among different serotypes of Cryptococcus gatti and Cryptococcus neoformans. Antimicorb Agents Chemother 2009; 53: 309311.
  • 56
    Clinical and Laboratory Standards Institute. Zone Diameter Interpretive Stantdards, Corresponding Minimal Inhibitory Concentration (MIC) Interpretive Breakpoints, and Quality Control Limits for Antifungal Disk Diffusion Susceptibility Testing of Yeasts. Clinical and Laboratory Standards Institute , Wayne , PA , 2007.
  • 57
    Thompson GR 3rd, Fothergill AW, Wiederhold NP, Vallor AC, Wickes BL, Patterson TF. Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2008; 52: 29592961.
  • 58
    Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A. Long-term outcome of AIDS cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006; 20: 21832191.
  • 59
    Shoham S, Cover C, Donegan N, Fulnecky E, Kumar P. Cryptococcus neoformans meningitis at 2 hospitals in Washington, DC: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2005; 40: 477479.
  • 60
    Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O. Major role for amphotericin B flucytosine combination in severe cryptococcosis. PloS One 2008; in press.
  • 61
    Leenders ACAP, DeMarie S, Ten Kate MT, Bakker-Woundenberg IAJM, Verbrugh HA. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. J Antimicrob Chemother 1996; 38: 215225.
  • 62
    Robinson PA, Bauer M, Leal MA et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999; 28: 8292.
  • 63
    Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 13831396.
  • 64
    Sun HY, Alexander BD, Lortholary O et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 2009: in press.
  • 65
    Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transplant 2008; 8: 426431.
  • 66
    Alexander BD, Perfect JR, Daly JS et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008; 86: 791796.
  • 67
    Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 11221131.
  • 68
    Saag MS, Cloud GA, Graybill JR et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated crytpcoccal meningitis. Clin Infect Dis 1999; 28: 291296.
  • 69
    Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation; a report of two cases. Transplant Proc 2004; 36: 27082709.
  • 70
    Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009 (in press).
  • 71
    Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, Fernandez CM, Boekhout T, Meis JF. In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008; 52: 15801582.
  • 72
    Morera-Lopez Y, Torres-Rodriguez JM, Jimenez-Cabello T, Baro-Tomas T. Cryptococcus gattii: In vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med Mycol 2005; 43: 505510.
  • 73
    Nooney L, Matthews RC, Burnie JP. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbio Infect Dis 2005: 1929.
  • 74
    Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: Current state of the science. Clin Infect Dis 2008; 47: 13211327.
  • 75
    Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7: 395401.